Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
about
Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practiceDrug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritisDrug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.Bococizumab for the treatment of hypercholesterolaemia.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment.Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.Reporting the response to anti-tumour necrosis factor treatment.Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?The economic case for precision medicine.Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
P2860
Q37383419-816644CA-D5EE-4C55-A017-4F2944289F44Q37484873-92168142-ECC1-41CA-98B8-38B373B56CDBQ37599165-864CE916-EAF3-4E58-A32F-46A4E03FD5BBQ37604498-389F611E-1381-4C0B-9533-B3AF6CEFB789Q37622219-88802865-954B-4BA1-B956-C25B91586674Q38648469-3C9D44B1-D9BA-4A79-8956-54C107C3969EQ38898145-C3788C04-6F37-4786-853B-37BD0AE321A6Q38991972-2A5FF035-EC61-4E07-8AC0-24DD944FDFFBQ39035931-0C2D8606-6571-4458-AB27-222C543254D1Q39042940-2457F28F-2AFE-4415-9280-7BDFE425AAA3Q39371316-11BD7ED7-01CE-446B-9CD0-696794EEA5FDQ39420995-59D55017-7C2E-46D2-B18A-5296836E2F40Q47107623-0D54A3F9-DBFE-4AB1-8F8C-DC0EFB8A6C05Q50014741-D064AFF8-B5CE-45FA-B619-6262760D590EQ50065301-70CD87D3-6BCC-46E0-B231-E5365CA4BAD9Q50083992-BF0556B5-4812-462D-B022-0A49E6F3A9CDQ51046105-B9CB6A40-CD2A-4C26-BD01-0F9D58BF9EE1Q51358152-5805C84D-C9D0-4DAC-B902-E525E22E9DE6Q51397182-67B2CE9C-0C02-47DC-AE24-F408C0157917Q55217201-F12CD818-51BA-4A6A-AA5D-60F417ADB2D9Q58779486-DB50BDEA-B31D-4B1D-AA0B-08EB77D98AE5
P2860
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical utility of random ant ...... ponse in rheumatoid arthritis.
@en
type
label
Clinical utility of random ant ...... ponse in rheumatoid arthritis.
@en
prefLabel
Clinical utility of random ant ...... ponse in rheumatoid arthritis.
@en
P2093
P2860
P50
P356
P1476
Clinical utility of random ant ...... ponse in rheumatoid arthritis.
@en
P2093
Ann W Morgan
Anthony G Wilson
Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators
Christopher E M Griffiths
Darren Plant
KimmeL Hyrich
Richard B Warren
P2860
P304
P356
10.1002/ART.39169
P577
2015-05-01T00:00:00Z